Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R-phenserine - Annovis Bio

Drug Profile

R-phenserine - Annovis Bio

Alternative Names: (+)-(3aR)-phenserine; (+)-phenserine; ANVS-401; ANVS-405; Posiphen

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute on Aging; National Institutes of Health (USA); Raptor Pharmaceutical Corp
  • Developer Annovis Bio; Cenomed BioSciences; Rockefeller University; University of California at Los Angeles
  • Class Nootropics; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; HD protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Mild cognitive impairment; Parkinson's disease
  • Phase I Down syndrome
  • Preclinical Traumatic brain injuries
  • No development reported Huntington's disease; Poisoning

Most Recent Events

  • 08 Aug 2019 Pharmacodynamics data from a preclinical trials in Traumatic brain injuries released by Annovis Bio
  • 01 Aug 2019 Preclinical development in Traumatic brain injuries is ongoing in USA (IV) (Annovis Bio pipeline, September 2019)
  • 24 Jun 2019 Annovis Bio plans a phase IIa trial for Parkinson’s disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top